Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
NCT ID: NCT01574235
Last Updated: 2015-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2114 participants
OBSERVATIONAL
2011-10-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
NCT02454530
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
NCT01459653
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
NCT00014456
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
NCT00115193
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
NCT02104830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Curative or prophylactic Nivestim® treatment for FN
Nivestim®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivestim®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients presenting with a solid tumor or a malignant hemopathy,
* Patients treated with or beginning treatment with neutropenia-inducing chemotherapy (regardless of the cycle),
* Patients in whom treatment with Nivestim® is instituted for the purpose of reducing the duration of the neutropenias and the incidence of the chemotherapy-induced febrile neutropenias
Exclusion Criteria
* Patients presenting with a myelodysplastic syndrome,
* Patients showing hypersensitivity to any of the ingredients of Nivestim®,
* Patients not receiving chemotherapy,
* Patients who were already included in the study during a previous chemotherapy line
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospira, now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Louis Pasteur
Colmar, Alsace, France
Hopital Jean Monnet
Épinal, Alsace, France
CH Emile Muller
Mulhouse, Alsace, France
CAC Paul Strauss
Strasbourg, Alsace, France
Chu Hopital Civil
Strasbourg, Alsace, France
STE ANNE
Strasbourg, Alsace, France
MEDIPOLE
Aix-les-Bains, Auvergne-Rhône-Alpes, France
CHRA
Annecy, Auvergne-Rhône-Alpes, France
Clinique CONVERT
Bourg-en-Bresse, Auvergne-Rhône-Alpes, France
Ch Chambery
Chambéry, Auvergne-Rhône-Alpes, France
Chu Grenoble
Grenoble, Auvergne-Rhône-Alpes, France
Ch Valence
Valence, Auvergne-Rhône-Alpes, France
Polyclinique Cesson
Cesson, Basse Normandie, France
Chu Rennes
Rennes, Basse Normandie, France
CHU SUD
Rennes, Basse Normandie, France
Clinique St Laurent
Rennes, Basse Normandie, France
Chp St Greg
Saint-Grégoire, Basse Normandie, France
Ch St Malo
St-Malo, Basse Normandie, France
CHG William MOREY
Chalon S/s, Bourgogne-Franche-Comté, France
CHU du BOCAGE
Dijon, Bourgogne-Franche-Comté, France
Clinique St Faron
Meaux, Champagne, France
Cac Jean Godinot
Reims, Champagne, France
Hopital St Quentin
Saint-Quentin, Champagne, France
Hopital Troyes
Troyes, Champagne, France
CHG Dieppe
Dieppe, Haute Normandie, France
Clinique Pasteur
Évreux, Haute Normandie, France
CH Jacques Monod
Montivilliers, Haute Normandie, France
Centre frederic joliot curie
Rouen, Haute Normandie, France
CHG
Alès, Languedoc, France
CHG
Béziers, Languedoc, France
CHG
Carcassonne, Languedoc, France
Chu St Eloi
Montpellier, Languedoc, France
Clinique Beausoleil
Montpellier, Languedoc, France
CHU Caremeau
Nîmes, Languedoc, France
Chg St Jean
Perpignan, Languedoc, France
Ch Du Pays D'Aix
Aix-en-Provence, Marseille, France
Clinique Rambot
Aix-en-Provence, Marseille, France
Ch Duffaut
Avignon, Marseille, France
Chp Clairval
Marseille, Marseille, France
Chu Timone
Marseille, Marseille, France
Fondation Saint Joseph
Marseille, Marseille, France
Hopital A.Pare
Marseille, Marseille, France
IPC
Marseille, Marseille, France
Chr Brive
Brivé, Massif Central, France
Chu Estaing
Clermont, Massif Central, France
Chu Gabriel Montpied
Clermont, Massif Central, France
Pole Sante Republique
Clermont, Massif Central, France
Clinique Vitalia Desertines
Montluçon, Massif Central, France
CHR
Roanne, Massif Central, France
Icl St Etienne
Saint-Etienne, Massif Central, France
CHG Cahors
Cahors, Midi Pyrennees, France
CHG St Gaudens
Saint-Gaudens, Midi Pyrennees, France
Clinique de l'Ormeau
Tarbes, Midi Pyrennees, France
CHU Purpan
Toulouse, Midi Pyrennees, France
Clinique Pasteur
Toulouse, Midi Pyrennees, France
Inst. Claudius Regaud
Toulouse, Midi Pyrennees, France
Clinique des Bonnettes
Arras, Nord, France
CH Boulogne-sur-Mer
Boulogne, Nord, France
Centre Oscar Lambret
Lille, Nord, France
Clinique des Dentellieres
Valenciennes, Nord, France
CH de Draguignan
Draguignan, Paca, France
CHI de Fréjus
Fréjus, Paca, France
Chi Frejus - St Raphael
Fréjus, Paca, France
CHICAS
Gap, Paca, France
Clinique Ste Marguerite
Hyères, Paca, France
Clinique du Cap d'Or
La Seyne-sur-Mer, Paca, France
Clinique Belvédère
Nice, Paca, France
CH Sainte Musse
Toulon, Paca, France
H.I.A Saint Anne
Toulon, Paca, France
Victor Dubos
Argenteuil, Paris Nord, France
Clinique Ste Marie
Osny, Paris Nord, France
Saint Antoine
Paris, Paris Nord, France
Saint Louis
Paris, Paris Nord, France
TENON
Paris, Paris Nord, France
Hpt Rene Dubos
Pontoise, Paris Nord, France
Clinique Porte St Cloud
Boulogne, Paris Ouest, France
BEAUJON
Clichy, Paris Ouest, France
Hopital Mignot
Le Chesnay, Paris Ouest, France
Hopital Franco Britannique
Levallois-Perret, Paris Ouest, France
Hopital Des Courses
Maisons-Laffitte, Paris Ouest, France
HARTMANN
Neuilly/seine, Paris Ouest, France
Centre Rene Huguenin
Saint-Cloud, Paris Ouest, France
Hopital Foch
Suresnes, Paris Ouest, France
Ico Angers
Angers, Pays de la Loire Region, France
Ch Cholet
Cholet, Pays de la Loire Region, France
Ch Le Mans
Le Mans, Pays de la Loire Region, France
Victor Hugo
Le Mans, Pays de la Loire Region, France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C. Study design: two long-term observational studies of the biosimilar filgrastim Nivestim (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. BMC Cancer. 2013 Nov 16;13:547. doi: 10.1186/1471-2407-13-547.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEXT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.